Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III R-ICE vs R-DHAP for relapsed diffuse large B-cell lymphoma eligible for transplant
2004-002103-32Phase 3Completed
- Sponsor
- GELA-RC
- Start
- Aug 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by GELA-RC. Primary endpoint: Overall response rate after 3 cycles adjusted for successful stem cell mobilization. Started Aug 2004; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2004-002103-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002103-32.